Association between somatostatin receptor 5 gene polymorphisms and pancreatic cancer risk and survival

Cancer

Volumn 117, Issue 13, 2011, Pages 2863-2872

  Li, Donghui ^a   Tanaka, Motofumi ^a   Brunicardi, F Charles ^b   Fisher, William E ^b   Gibbs, Richard A ^b   Gingras, Marie Claude ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

pancreatic cancer risk; single nucleotide polymorphism; smoking.; Somatostatin receptor 5; survival

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SOMATOSTATIN RECEPTOR 5 GENE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; RECEPTORS, SOMATOSTATIN; RETROSPECTIVE STUDIES; RISK; SEQUENCE ANALYSIS, DNA; SMOKING; SOMATOSTATIN;

EID: 79959590048     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25858     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ., Cancer statistics, 2009. CA Cancer J Clin. 2009; 59: 225-249.
2. Li D, Morris JS, Liu J, et al. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA. 2009; 301: 2553-2562.
3. Raimondi S, Maisonneuve P, Lowenfels AB., Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol. 2009; 6: 699-708.
4. Hejna M, Schmidinger M, Raderer M., The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing? Ann Oncol. 2002; 13: 653-668. (Pubitemid 34567371)
5. Butturini G, Bettini R, Missiaglia E, et al. Predictive factors of efficacy of the somatostatin analogue octreotide as first-line therapy for advanced pancreatic endocrine carcinoma. Endocr Relat Cancer. 2006; 13: 1213-1221. (Pubitemid 46212575)
6. Canobbio L, Cannata D, Miglietta L, et al. Somatuline (BIM 23014) and tamoxifen treatment of postmenopausal breast cancer patients: clinical activity and effect on insulin-like growth factor-I (IGF-I) levels. Anticancer Res. 1995; 15: 2687-2690. (Pubitemid 26095083)
7. Raderer M, Hamilton G, Kurtaran A, et al. Treatment of advanced pancreatic cancer with the long-acting somatostatin analogue lanreotide: in vitro and in vivo results. Br J Cancer. 1999; 79: 535-537. (Pubitemid 29046232)
8. Pollak MN, Schally AV., Mechanisms of antineoplastic action of somatostatin analogs. Proc Soc Exp Biol Med. 1998; 217: 143-152.
9. Reubi JC, Waser B, Schaer JC, Laissue JA., Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med. 2001; 28: 836-846. (Pubitemid 32662546)
10. Li M, Li W, Kim HJ, Yao Q, Chen C, Fisher WE., Characterization of somatostatin receptor expression in human pancreatic cancer using real-time RT-PCR. J Surg Res. 2004; 119: 130-137. (Pubitemid 38625638)
11. Butler AA, Yakar S, LeRoith D., Insulin-like growth factor-I: compartmentalization within the somatotropic axis? News Physiol Sci. 2002; 17: 82-85.
12. Yu H, Rohan T., Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst. 2000; 92: 1472-1489.
13. Johansson M, McKay JD, Wiklund F, et al. Genetic variation in the SST gene and its receptors in relation to circulating levels of insulin-like growth factor-I, IGFBP3, and prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2009; 18: 1644-1650.
14. Canzian F, McKay JD, Cleveland RJ, et al. Genetic variation in the growth hormone synthesis pathway in relation to circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3, and breast cancer risk: results from the European prospective investigation into cancer and nutrition study. Cancer Epidemiol Biomarkers Prev. 2005; 14: 2316-2325. (Pubitemid 41437831)
15. Taniyama Y, Suzuki T, Mikami Y, Moriya T, Satomi S, Sasano H., Systemic distribution of somatostatin receptor subtypes in human: an immunohistochemical study. Endocr J. 2005; 52: 605-611. (Pubitemid 41609051)
16. Szepeshazi K, Schally AV, Halmos G, et al. Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptor subtypes 5 and/or 3 in experimental pancreatic cancers. Clin Cancer Res. 2001; 7: 2854-2861. (Pubitemid 32911395)
17. Hassan MM, Bondy ML, Wolff RA, et al. Risk factors for pancreatic cancer: case-control study. Am J Gastroenterol. 2007; 102: 2696-2707. (Pubitemid 350179330)
18. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N., Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst. 2004; 96: 434-442. (Pubitemid 38443646)
19. Lee PH, Shatkay H., F-SNP: computationally predicted functional SNPs for disease association studies. Nucleic Acids Res. 2008; 36: D820-D824. (Pubitemid 351149829)
20. Patel YC, Greenwood MT, Panetta R, Demchyshyn L, Niznik H, Srikant CB., The somatostatin receptor family. Life Sci. 1995; 57: 1249-1265.
21. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M., Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004; 363: 1346-1353. (Pubitemid 38529873)
22. Wolpin BM, Michaud DS, Giovannucci EL, et al. Circulating insulin-like growth factor axis and the risk of pancreatic cancer in four prospective cohorts. Br J Cancer. 2007; 97: 98-104. (Pubitemid 47012086)
23. Bergmann U, Funatomi H, Yokoyama M, Beger HG, Korc M., Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res. 1995; 55: 2007-2011.
24. Filopanti M, Ronchi C, Ballarè E, et al. Analysis of somatostatin receptors 2 and 5 polymorphisms in patients with acromegaly. J Clin Endocrinol Metab. 2005; 90: 4824-4828. (Pubitemid 41159378)
25. Hoyo C, Grubber J, Demark-Wahnefried W, et al. Predictors of variation in serum IGF1 and IGFBP3 levels in healthy African American and white men. J Natl Med Assoc. 2009; 101: 711-716.